OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum
OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum
Homepage   /    business   /    OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum

OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum

🕒︎ 2025-10-29

Copyright Seeking Alpha

OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum

OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum Oct. 28, 2025 8:22 PM ETOrthoPediatrics Corp. (KIDS) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: OrthoPediatrics Corp. (KIDS) Q3 2025 Management View David Bailey, President and CEO, reported that "in the third quarter, we supported the treatment of more than 37,100 children, increasing our total impact to approximately 1.3 million kids' health." He highlighted strength across all core business Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Delays in 7D sales and LatAm set sales caused lower revenue guidance and added risk, but management views the impact as temporary, expects improved profitability from focusing on higher-margin segments, and is exploring new distributor structures to mitigate future volatility. Management reiterated guidance for positive free cash flow in Q4 and reaching break-even in 2026, with improved cash flow usage and operational changes supporting these targets despite lower top-line growth. Core segments delivered strong growth rates, robust clinic expansion, and margin gains. Analysts questioned longevity but management expressed confidence in continued innovation, competitive gains, and asset leverage supporting ongoing strength. Recommended For You More Trending News

Guess You Like

White House relaxes rule on $100,000 H1b fee. Here's what we know
White House relaxes rule on $100,000 H1b fee. Here's what we know
U.S. Citizenship and Immigrati...
2025-10-22